MIRM News and Press, Mirum Pharmaceuticals Inc. From 02/05/26

- Authorization includes oral solution and tablet formulation to support flexible dosing Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI ® (maralixibat) oral solution and tablet formu...

2026-01-31 15:22:00 ET Mirum Pharmaceuticals (NASDAQ: MIRM) , a mid-cap biotech, performed well last year and is maintaining that momentum so far in 2026. The company's shares have more than doubled over the trailing 12-month period. However, as is almost always the case with sm...

2026-01-27 03:15:00 ET Mirum Pharmaceuticals ' (NASDAQ: MIRM) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons. In several important ways, Mirum is at an inflection point. It...

2026-01-26 09:19:21 ET Fast Facts About the Direxion Daily S&P Biotech Bear 3x Shares ETF Read the full article on Seeking Alpha For further details see: LABD: ETF To Benefit From Downturns In The Biotech Industry

- Adds brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations to Mirum’s portfolio - Topline Phase 3 results expected in 2H 2026 Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced th...

2026-01-14 17:16:02 ET Mirum Pharmaceuticals, Inc. (MIRM) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 2:15 PM EST... Read the full article on Seeking Alpha For further details see: Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Heal...

2026-01-13 05:04:00 ET The new year isn't looking so new now. January is already nearly halfway over. Before you know it, we'll be looking ahead to 2027. No one can slow down the hands of time. It's important to seize great opportunities as soon as possible. That's why I believe the fol...

2026-01-12 15:05:12 ET from Robert W. Baird issued a price target of $95.00 for MIRM on 2026-01-12 19:53:29. The adjusted price target was set to $95.00. At the time of the announcement, MIRM was trading at $89.5. The overall price target consensus is at $102.20 with hig...

- 2025 net product sales of approximately $520 million (preliminary and unaudited) exceed upper end of guidance - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected Q2 2026...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 11:15 a.m. PT. The presentation and question and answer session will be ...